Table of Contents

company-logo

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus Dividend Announcement

• Agenus does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Agenus dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Agenus Dividend History

Agenus Dividend Yield

Agenus current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Agenus stock? Use our calculator to estimate your expected dividend yield:

Agenus Financial Ratios

P/E ratio-0.44
PEG ratio0.01
P/B ratio-0.41
ROE122.08%
Payout ratio0.00%
Current ratio0.37
Quick ratio0.37
Cash Ratio0.35

Agenus Dividend FAQ

Does Agenus stock pay dividends?
Agenus does not currently pay dividends to its shareholders.
Has Agenus ever paid a dividend?
No, Agenus has no a history of paying dividends to its shareholders. Agenus is not known for its dividend payments.
Why doesn't Agenus pay dividends?
There are several potential reasons why Agenus would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Agenus ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Agenus has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Agenus a dividend aristocrat?
Agenus is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Agenus a dividend king?
Agenus is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Agenus a dividend stock?
No, Agenus is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Agenus stocks?
To buy Agenus you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Agenus stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.